Table 4 Incidence of various clinical manifestations of cardiotoxicity in the patients
From: Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
Clinical manifestations | All patients (n = 527) | 5-fluorouracil (n = 196) | Capecitabine (n = 331) |
|---|---|---|---|
Heart failure | 20 (3.8) | 5 (2.6) | 15 (4.5) |
Myocardial infarction | 6 (1.1) | 2 (1.0) | 4 (1.2) |
Arrhythmia | 110 (20.9) | 33 (16.8) | 77 (23.3) |
 Sinus bradycardia | 42 (8.0) | 11 (5.6) | 31 (9.1) |
 Premature beat | 33 (6.3) | 10 (5.1) | 23 (7.0) |
 Conduction block | 28 (5.3) | 9 (4.6) | 19 (5.7) |
 Sinus tachycardia | 26 (4.9) | 11 (5.6) | 15 (4.5) |
 Atrial fibrillation | 2 (0.4) | 0 (0.0) | 2 (0.6) |
Ischemic change | 105 (19.9) | 39 (19.9) | 66 (19.9) |
 ST segment | 70 (13.3) | 23 (11.7) | 47 (14.2) |
 T segment | 48 (9.1) | 21 (10.7) | 27 (8.2) |
 P segment | 9 (1.7) | 3 (1.5) | 6 (1.8) |
 R segment | 3 (0.6) | 1 (0.5) | 2 (0.6) |
Total patients | 161 (30.6) | 49 (25.0) | 112 (33.8) |